BR0213434A - Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável - Google Patents
Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitávelInfo
- Publication number
- BR0213434A BR0213434A BR0213434-9A BR0213434A BR0213434A BR 0213434 A BR0213434 A BR 0213434A BR 0213434 A BR0213434 A BR 0213434A BR 0213434 A BR0213434 A BR 0213434A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- rosuvastatin
- pharmaceutically acceptable
- acceptable salt
- dementia
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
- 229960000672 rosuvastatin Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
| PCT/SE2002/001911 WO2003032995A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213434A true BR0213434A (pt) | 2004-11-09 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213434-9A BR0213434A (pt) | 2001-10-19 | 2002-10-18 | Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (enExample) |
| EP (1) | EP1446123A1 (enExample) |
| JP (1) | JP2005505605A (enExample) |
| KR (1) | KR20040058201A (enExample) |
| CN (1) | CN1604780A (enExample) |
| AR (1) | AR036891A1 (enExample) |
| BR (1) | BR0213434A (enExample) |
| CA (1) | CA2463597A1 (enExample) |
| CO (1) | CO5580773A2 (enExample) |
| HU (1) | HUP0401798A3 (enExample) |
| IL (1) | IL161380A0 (enExample) |
| IS (1) | IS7218A (enExample) |
| MX (1) | MXPA04003631A (enExample) |
| NO (1) | NO20041840L (enExample) |
| PL (1) | PL369573A1 (enExample) |
| RU (1) | RU2004112422A (enExample) |
| SE (1) | SE0103509D0 (enExample) |
| WO (1) | WO2003032995A1 (enExample) |
| ZA (1) | ZA200402844B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| CN1894221B (zh) | 2003-12-02 | 2012-08-08 | 特瓦制药工业有限公司 | 用于表征罗苏伐他汀的参照标准品 |
| WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| TWI345562B (en) | 2005-02-22 | 2011-07-21 | Teva Pharma | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| KR20070062996A (ko) | 2005-08-16 | 2007-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 로수바스타틴 중간체 |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060229321A1 (en) | 2006-10-12 |
| EP1446123A1 (en) | 2004-08-18 |
| PL369573A1 (en) | 2005-05-02 |
| HUP0401798A3 (en) | 2005-06-28 |
| RU2004112422A (ru) | 2005-04-10 |
| HUP0401798A2 (hu) | 2005-01-28 |
| ZA200402844B (en) | 2005-01-24 |
| CN1604780A (zh) | 2005-04-06 |
| CA2463597A1 (en) | 2003-04-24 |
| SE0103509D0 (sv) | 2001-10-19 |
| WO2003032995A1 (en) | 2003-04-24 |
| IL161380A0 (en) | 2004-09-27 |
| JP2005505605A (ja) | 2005-02-24 |
| WO2003032995A8 (en) | 2004-06-03 |
| AR036891A1 (es) | 2004-10-13 |
| NO20041840L (no) | 2004-05-05 |
| CO5580773A2 (es) | 2005-11-30 |
| KR20040058201A (ko) | 2004-07-03 |
| MXPA04003631A (es) | 2004-07-30 |
| IS7218A (is) | 2004-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312947A (pt) | terapias para insuficiência renal empregando-se interferon-beta | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| BR0014996A (pt) | Método para prevenir ou melhorar a dor de um ferimento fechado cirurgicamente em um indivìduo, e, emplastro | |
| BR0115511A (pt) | Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo | |
| BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
| DE69721766D1 (de) | Neue arzneiformulierung | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| NO922380L (no) | Substituerte 4-fenyl-4-piperidinkarboksamider med baade lokal anestetisk og analgetisk effekt samt fremgangsmaater for deres fremstilling | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR9916860A (pt) | Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma | |
| BR0314844A (pt) | Novo composto | |
| BR9813208A (pt) | Antagonista receptor de vitronectina | |
| BR0314843A (pt) | Novo composto | |
| ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
| BR0011578A (pt) | Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico | |
| EP1266663A4 (en) | EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS | |
| BR0010084A (pt) | Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto | |
| BR0313655A (pt) | Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável | |
| PT986393E (pt) | Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro | |
| DK0866711T3 (da) | Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö | |
| BR9910185A (pt) | Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| MXPA04003631A (es) | Rosuvastatina en estados de pre-demencia. | |
| BR0211358A (pt) | Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |